DNTH
Price
$17.63
Change
-$0.50 (-2.76%)
Updated
Jun 27 closing price
Capitalization
566.66M
ERAS
Price
$1.26
Change
-$0.00 (-0.00%)
Updated
Jun 27 closing price
Capitalization
364.02M
39 days until earnings call
Interact to see
Advertisement

DNTH vs ERAS

Header iconDNTH vs ERAS Comparison
Open Charts DNTH vs ERASBanner chart's image
Dianthus Therapeutics
Price$17.63
Change-$0.50 (-2.76%)
Volume$789.41K
Capitalization566.66M
Erasca
Price$1.26
Change-$0.00 (-0.00%)
Volume$1.66K
Capitalization364.02M
DNTH vs ERAS Comparison Chart in %
Loading...
DNTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNTH vs. ERAS commentary
Jun 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNTH is a Buy and ERAS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 29, 2025
Stock price -- (DNTH: $17.63 vs. ERAS: $1.26)
Brand notoriety: DNTH and ERAS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNTH: 294% vs. ERAS: 0%
Market capitalization -- DNTH: $566.66M vs. ERAS: $364.02M
DNTH [@Biotechnology] is valued at $566.66M. ERAS’s [@Biotechnology] market capitalization is $364.02M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNTH’s FA Score shows that 0 FA rating(s) are green whileERAS’s FA Score has 1 green FA rating(s).

  • DNTH’s FA Score: 0 green, 5 red.
  • ERAS’s FA Score: 1 green, 4 red.
According to our system of comparison, both DNTH and ERAS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNTH’s TA Score shows that 2 TA indicator(s) are bullish while ERAS’s TA Score has 3 bullish TA indicator(s).

  • DNTH’s TA Score: 2 bullish, 5 bearish.
  • ERAS’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, both DNTH and ERAS are a bad buy in the short-term.

Price Growth

DNTH (@Biotechnology) experienced а +4.60% price change this week, while ERAS (@Biotechnology) price change was -8.03% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

ERAS is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNTH($567M) has a higher market cap than ERAS($364M). DNTH YTD gains are higher at: -19.128 vs. ERAS (-49.801). DNTH has higher annual earnings (EBITDA): -116.76M vs. ERAS (-150.24M). ERAS has more cash in the bank: 305M vs. DNTH (263M). DNTH has less debt than ERAS: DNTH (1.4M) vs ERAS (50.8M). DNTH has higher revenues than ERAS: DNTH (6.52M) vs ERAS (0).
DNTHERASDNTH / ERAS
Capitalization567M364M156%
EBITDA-116.76M-150.24M78%
Gain YTD-19.128-49.80138%
P/E Ratio3.24N/A-
Revenue6.52M0-
Total Cash263M305M86%
Total Debt1.4M50.8M3%
FUNDAMENTALS RATINGS
DNTH: Fundamental Ratings
DNTH
OUTLOOK RATING
1..100
11
VALUATION
overvalued / fair valued / undervalued
1..100
50
Fair valued
PROFIT vs RISK RATING
1..100
63
SMR RATING
1..100
95
PRICE GROWTH RATING
1..100
80
P/E GROWTH RATING
1..100
67
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
DNTHERAS
RSI
ODDS (%)
N/A
Bearish Trend 3 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
90%
Momentum
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
86%
MACD
ODDS (%)
Bullish Trend 3 days ago
85%
Bearish Trend 3 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
79%
Bearish Trend 3 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
78%
Advances
ODDS (%)
N/A
N/A
Declines
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 4 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
83%
Bullish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
DNTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TRGAX22.200.22
+1.00%
T. Rowe Price Global Industrials I
CSECX33.750.16
+0.48%
Calvert Equity C
FIIAX22.490.10
+0.45%
Fidelity Advisor Mid Cap II A
RYMVX73.05-0.24
-0.33%
Rydex S&P MidCap 400 Pure Value A
KSOCX152.40-1.36
-0.88%
Kinetics Small Cap Opportunities Adv C

DNTH and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNTH has been loosely correlated with IMNM. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if DNTH jumps, then IMNM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNTH
1D Price
Change %
DNTH100%
-2.76%
IMNM - DNTH
51%
Loosely correlated
-0.23%
ERAS - DNTH
50%
Loosely correlated
N/A
CRNX - DNTH
48%
Loosely correlated
-0.10%
XNCR - DNTH
48%
Loosely correlated
-3.10%
SYRE - DNTH
47%
Loosely correlated
-4.99%
More

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with RVMD. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then RVMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
N/A
RVMD - ERAS
57%
Loosely correlated
-1.52%
XNCR - ERAS
53%
Loosely correlated
-3.10%
APGE - ERAS
52%
Loosely correlated
N/A
IMNM - ERAS
51%
Loosely correlated
-0.23%
LRMR - ERAS
51%
Loosely correlated
N/A
More